The asset
The acquisition centres on Calytrix's lead experimental programme, a preclinical antibody designed to treat essential thrombocythemia and myelofibrosis driven by mutations in the calreticulin protein. Both conditions belong to a group of diseases known as myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of abnormal blood cells.
The antibody is designed to target both Type 1 and Type 2 mutant calreticulin, with the aim of eliminating the disease-driving cells while preserving healthy tissue and blood-cell production.
Calytrix said existing drug treatments for the two conditions primarily manage symptoms and complications, creating an opportunity for therapies that target the underlying mutations and potentially alter the course of the diseases. However, the programme remains at the preclinical stage and must undergo clinical development before its safety and effectiveness in patients can be established.